CLSI eNews - 1 December 2005 (Plain Text Version)

Return to Graphical Version | Search back issues | Print all articles

In this issue:
Note on printing single articles: Each selected individual article will appear at the bottom of this screen...please scroll down to view/print the selected article.

News
Executive Vice President's Message
CLSI 2005 Survey Results Reflect Market Views, Needs
Announcing 2006 Leadership Conference
CLSI Honor Roll and 2006 Awards Nominations
Press Releases
Standards Status
Vote and Deadlines
Recently Approved Documents
Call for Nominations
Events and Exhibits
Upcoming Events
Upcoming Presentations
CLSI Meetings Calendar
Participate in CLSI
Volunteer
New and Sustaining Members
Update Your Subscription

Recently Approved Documents

Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Second Edition (M39-A2)

M39-A2—Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Second Edition
This document provides guidelines for clinical laboratories and their data analysis software providers on the routine generation and storage of susceptibility data, and the compilation of susceptibility statistics. M39-A2 provides recommendations for consistent and effective use of cumulative susceptibility statistics, to enable clinicians to select the most appropriate agents for empiric antimicrobial therapy. Updates include expanded rationale behind including only the "first isolate per patient" in analyzing data; guidelines for data presentation; and expanded guidelines for presenting data to reflect new resistance trends.
Purchase here.

Second Notice

EP7-A2—Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition
Promoting uniformity in evaluating interference characteristics in clinical laboratory measurement procedures, EP7 describes procedures for manufacturers to screen potentially interfering substances, quantify interference effects, and confirm interference in patient samples. The guideline also describes procedures for clinical laboratories to verify interference claims, and to investigate discrepant results caused by unsuspected interfering substances. Includes background information on interference testing concepts, tables of recommended test concentrations for analytes and potential interference, and data collection and analysis worksheets.
Purchase here.

Our procedures have been designed to ensure that consensus has been achieved when a standard or guideline is published at the approved level. This means that a document has been rigorously reviewed by the authoring subcommittee, the area committee overseeing the project, the Board of Directors, and the medical-testing community that participates in the consensus process by carefully reviewing and commenting on the standard or guideline.

You may automatically receive or select approved-level documents as a member benefit. Find out more about joining CLSI: view membership options and benefits.